Literature DB >> 33963914

Does preoperative neoadjuvant chemotherapy impact short-term surgical outcomes in patients with locally advanced colon cancer?

Ryan Silva1, Mohammad Hamidi1, Pamela Omesiete1, Fawsia Osman1, Casey Charlton1, Shoujit Banerjee1, Timothy Estrada1, Valentine Nfonsam2.   

Abstract

BACKGROUND: Preoperative neoadjuvant chemotherapy (NAC) for colon cancer in advanced stages is associated with improved outcomes and tumor regression. The aim of our study was to identify outcomes in patients with colon cancer who received preoperative NAC.
METHODS: A 4-year analysis of the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) was performed. We included patients with locally advanced colon cancer (non-metastatic T3, T4 with or without nodal involvement) who underwent colon cancer resection. Patients were stratified into two groups (NAC and No-NAC). Our outcome measures were anastomotic leaks, hospital length of stay (LOS), 30-day complications, 30-day mortality, and 30-day readmissions. We performed a multi-variable logistic regression analysis.
RESULTS: We analyzed 90,055 patients of which 7694 (NAC: 7.8 % (n = 599) and No-NAC: 92.2% (n = 7095)) met the inclusion criteria and included in the analysis. Mean age was 67 ± 13 years, 51% were males, and 72% were whites. Patients in the NAC group were more likely to be younger (60 ± 12 years vs. 68 ± 13 years, p < 0.01) and males (62% vs. 50%, p < 0.01) compared to No-NAC. On regression analysis, preoperative NAC was independently associated with higher odds of anastomotic leak (OR 1.35 [1.05-1.97], p = 0.03) and 30-day readmission (OR 1.54 [1.24-2.05], p < 0.01) in reference to No-NAC. However, no association was found between NAC and 30-day complications and 30-day mortality.
CONCLUSIONS: Preoperative NAC might be associated with adverse outcomes of anastomotic leaks and 30-day readmissions, however does not appear to impact 30-day complications nor 30-day mortality.

Entities:  

Keywords:  Colon cancer; Locally advanced; Neoadjuvant; chemotherapy

Year:  2021        PMID: 33963914     DOI: 10.1007/s00384-021-03949-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  15 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer?

Authors:  Zheng Zhou; Halla S Nimeiri; Al B Benson
Journal:  Ann Transl Med       Date:  2013-07

3.  Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial.

Authors:  Anders Jakobsen; Fahimeh Andersen; Anders Fischer; Lars H Jensen; Jens C R Jørgensen; Ole Larsen; Jan Lindebjerg; John Pløen; Søren R Rafaelsen; Jesper Vilandt
Journal:  Acta Oncol       Date:  2015-04-29       Impact factor: 4.089

4.  Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer.

Authors:  Ahmed Dehal; Amanda N Graff-Baker; Brooke Vuong; Trevan Fischer; Samuel J Klempner; Shu-Ching Chang; Gary L Grunkemeier; Anton J Bilchik; Melanie Goldfarb
Journal:  J Gastrointest Surg       Date:  2017-09-20       Impact factor: 3.452

5.  Multivisceral resection for colon carcinoma.

Authors:  Roland S Croner; Susanne Merkel; Thomas Papadopoulos; Vera Schellerer; Werner Hohenberger; Jonas Goehl
Journal:  Dis Colon Rectum       Date:  2009-08       Impact factor: 4.585

Review 6.  Multivisceral resection for T4 or recurrent colorectal cancer.

Authors:  J O Larkin; P R O'Connell
Journal:  Dig Dis       Date:  2012-11-23       Impact factor: 2.404

7.  Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.

Authors:  Mehdi Karoui; Anne Rullier; Alain Luciani; Franck Bonnetain; Marie-Luce Auriault; Antony Sarran; Geneviève Monges; Hervé Trillaud; Karine Le Malicot; Karen Leroy; Iradj Sobhani; Armelle Bardier; Marie Moreau; Isabelle Brindel; Jean François Seitz; Julien Taieb
Journal:  BMC Cancer       Date:  2015-07-10       Impact factor: 4.430

8.  Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer.

Authors:  Chun-Ming Huang; Ming-Yii Huang; Cheng-Jen Ma; Yung -Sung Yeh; Hsiang-Lin Tsai; Ching-Wen Huang; Chih-Jen Huang; Jaw-Yuan Wang
Journal:  Radiat Oncol       Date:  2017-03-07       Impact factor: 3.481

9.  Risk Factors of Anastomotic Leakage and Long-Term Survival After Colorectal Surgery.

Authors:  Jong Seob Park; Jung Wook Huh; Yoon Ah Park; Yong Beom Cho; Seong Hyeon Yun; Hee Cheol Kim; Woo Yong Lee
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

10.  Trends and Outcomes of Surgical Treatment for Colorectal Cancer between 2004 and 2012- an Analysis using National Inpatient Database.

Authors:  Meng-Tse Gabriel Lee; Chong-Chi Chiu; Chia-Chun Wang; Chia-Na Chang; Shih-Hao Lee; Matthew Lee; Tzu-Chun Hsu; Chien-Chang Lee
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.